RNA vaccines have demonstrated efficacy against SARS-CoV-2 in humans, and the
technology is being leveraged for rapid emergency response. In this report, we assessed …

Self-amplifying RNA vaccines may induce equivalent or more potent immune responses at
lower doses compared to non-replicating mRNA vaccines via amplified antigen expression …

Abstract mRNA vaccines were the first to be authorized for use against SARS-CoV-2 and
have since demonstrated high efficacy against serious illness and death. However …

Establishment of an mRNA vaccine platform in low-and middle-income countries (LMICs) is
important to enhance vaccine accessibility and ensure future pandemic preparedness. Here …

Abstract The coronavirus disease 2019 (COVID-19) pandemic continues to spread globally,
highlighting the urgent need for safe and effective vaccines that could be rapidly mobilized …

SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high
transmissibility of the virus and the high rate of morbidity and mortality associated with …

The spread of the SARS-CoV-2 into a global pandemic within a few months of onset
motivates the development of a rapidly scalable vaccine. Here, we present a self-amplifying …

Carrier-free naked mRNA vaccines may reduce the reactogenicity associated with delivery
carriers; however, their effectiveness against infectious diseases has been suboptimal. To …

The spread of the SARS-CoV-2 into a global pandemic within a few months of onset
motivates the development of a rapidly scalable vaccine. Here, we present a self-amplifying …

Although inoculation of COVID-19 vaccines has rolled out globally, there is still a critical
need for safe and effective vaccines to ensure fair and equitable supply for all countries …